Influenza A Virus (H3N2)NIAID
#17,456
While flu vaccines have been around since the 1940s, after 80 years - and many improvements (cell culture-propagated vaccines , adjuvanted and high dose vaccines, quadrivalent formulas, etc.) - most years they still only provide modest protection against influenza infection, and are pretty much `strain-specific'.
A universal flu vaccine is often described in the popular press as being a `one time (or every few years) shot' that would convey nearly full protection against all flu sub-types. While ideal, the current goal is a bit more modest.The holy grail of vaccinology is the creation of a `Universal Flu Vaccine', a goal that has been described for decades as being `five years away'. A statement that still holds true today.
Despite these reduced goals, the road to a universal flu shot is a long one, and success - at least in the near term - is far from guaranteed (see Scripps Research: Study Suggests Some Flu Viruses May Be Less Susceptible To A `Universal' Flu Vaccine).
Last year, in NIH Begins Clinical Trial On A Universal Flu Vaccine Candidate we looked at another trial using 4 inactivated LPAI (avian flu) viruses (H7N3, H5N1, H3N8, and H1N9), but that trial is still ongoing, and isn't scheduled to end until March 2024.
Yesterday the NIH has announced a new trial, this time using an mRNA vaccine candidate, that is scheduled to run through August of 2024. While this mRNA vaccine will still target the HA (hemagglutinin) gene segment, it will focus on the stem, which is less mutable and more conserved than the head across influenza subtypes.
This press release comes from the NIH.
Clinical trial of mRNA universal influenza vaccine candidate begins
A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), part of the National Institutes of Health, has begun enrolling volunteers at Duke University in Durham, North Carolina. This Phase 1 trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
The trial will enroll up to 50 healthy volunteers aged 18 through 49. Three groups of study participants (10 participants each) will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine, respectively. After evaluation of the data to determine an optimum dosage, an additional 10 participants will be enrolled to receive the optimum dosage. The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine. This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines. Participants will be regularly evaluated to assess the vaccine’s safety (and, secondarily, its efficacy) and will receive follow-up appointments for up to one year after vaccination.
Seasonal influenza, or flu, kills thousands of people in the United States each year. The Centers for Disease Control and Prevention estimates that between 2010 and 2020, between 12,000 and 52,000 people died of flu in the United States annually(link is external). Although annual seasonal flu vaccines are valuable tools in controlling the spread and severity of influenza, they do not provide immunity against every flu strain. Each year, before the flu season begins, scientific experts must predict which influenza strains are likely to be most common during the upcoming months and then select three or four of these strains to include in the next seasonal flu vaccine. Vaccine manufacturers then need time to produce and distribute the vaccine—during which the dominant strains of the virus can change in unexpected ways, potentially decreasing the efficacy of the vaccine. An effective universal flu vaccine could eliminate these problems by protecting its recipients against a wide variety of strains and ideally providing durable long-term immunity, so people would not need to be vaccinated every year.
“A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines, as well as the need for patients to get a flu shot each year,” said Acting NIAID Director Hugh Auchincloss, M.D. “Moreover, some strains of influenza virus have significant pandemic potential. A universal flu vaccine could serve as an important line of defense against the spread of a future flu pandemic.”
The early-stage trial is being conducted through the Collaborative Influenza Vaccine Innovation Centers (CIVICs)(link is external) program, which was created by NIAID in 2019 to support the development of broadly protective and longer-lasting flu vaccines. It is the first investigational universal flu vaccine candidate to be tested by the CIVICs program, and was manufactured at the facilities of the Duke Human Vaccine Institute (DHVI), which is a part of the CIVICs program.
A similar vaccine developed by researchers at NIAID’s VRC already has shown positive results in early clinical trials. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza. While one portion of the HA protein, known as the head, tends to change as the flu virus spreads and evolves, a more stable portion, known as the stem, evolves very slowly and is very similar across many different types of the flu virus. By using the HA stem as the basis for a vaccine, researchers hope to induce long-term immunity against a broad range of flu viruses. Unlike the VRC’s earlier vaccine, the H1ssF-3928 mRNA-LNP vaccine candidate uses a messenger RNA (mRNA) platform. By developing and testing a variety of different platforms for a universal flu vaccine, researchers are more likely to find one that is both safe and provides strong and broad immunity against a variety of strains.
For more information about the clinical trial, visit clinicaltrials.gov using the identifier NCT05755620.
(Continue . . . )